Biotech Values

[ghmm]

GLPG / INCY:

Thanks for the correction on the INCY royalty I should have looked at the INCY filing rather than an article. My point was more to the wide apparent disparity in value the market is giving for US rights for the JAKs of the two companies. I actually like what Gilead is doing beyond RA if no major safety issues this could be a really big class of drugs (assuming FDA is actually going to approve another JAK).

Someone on twitter posted this about an investor call with the company. I haven't dialed in (the post says its available to the 25th) in the notes INCY management thinks the CRL is related to data in the major amendment for what its worth.

http://www.twitlonger.com/show/n_1spq7gn

h/t to B I O T E C H @_B_I_O_T_E_C_H_ for the notes/call info.

The UBS analyst thought some CV events and rate of infections in Phase 3.